Inivata Raises $390 million Acquisition

Inivata has raised $390M in Acquisition funding led by NeoGenomics. Integrate Inivata LiquidIQ platform into NeoGenomics offering. The funds will be used to Integrate Inivata LiquidIQ platform into NeoGenomics offering.

What it does

Integrate Inivata LiquidIQ platform into NeoGenomics offering. This addresses liquid Biopsy Market is Expected to Witness Robust Growth by 2032, Estimates DelveInsight.

Traction

Liquid Biopsy Market is Expected to Witness Robust Growth by 2032, Estimates DelveInsight The company is using its latest financing to scale, with the Acquisition round serving as the clearest current traction signal in the source bundle.

Trend impact

Liquid Biopsy Market is Expected to Witness Robust Growth by 2032, Estimates DelveInsight As adoption in Healthcare & Life Sciences expands, focused products from Inivata can pressure incumbents or broader platforms that do not address the same problem directly.

Funding history

• June 1, 2021 · Acquisition · $390 million · NeoGenomics

Products & services

• Liquid Biopsy Market is Expected to Witness Robust Growth by 2032, capability
• Estimates DelveInsight - Barchart. Liquid Biopsy Market is Expected to capability
• Witness Robust Growth by 2032, Estimates DelveInsight - Barchart capability
• Barchart Fusion Biopsy Market Size Worth USD 803.50 Mn by 2035 Amid capability
• Rising Adoption of Precision Prostate Cancer Diagnostics - BioSpace. capability